NCT04209829Not yet recruiting
Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics
Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies (Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma) Depending on Tumor Characteristics
Source: ClinicalTrials.gov · Last updated 24 Dec 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment. The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 22 Nov 2019
- Start date
- Dec 2019
- Primary completion date
- Mar 2025
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT04209829
What you commit to
- Study type: Observational
- Planned participants: 600
- From Dec 2019 to the primary completion date, Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patient treated with another treatment than CAR-T Cells
Other illness
- patient with other hematological malignancies than lymphoma, LAL or MM
Other
- patient's weight \<58 kg
- patient under tutorship or curatorship
- patient not covered by a health system
Who the study is looking for
- patient with hematological malignancy (lymphoma, ALL, MM)
- patient integrated into a CAR-T Cells program treatment
- patient aged 15 years or over
- patient having signed a written consent; as well as his legal representative if \<18 years old
Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.